PepGen 肌营养不良药物早期试验结果积极
STAT+: PepGen says early trial for muscular dystrophy drug looks promising
PepGen 公司的实验药物在肌营养不良(DM1)治疗中显示出了最积极的早期数据,来自6名患者12周的治疗结果显示了良好前景。尽管如此,该领域仍面临挑战,因为Dyne Therapeutics的DM1药物在关键指标上未见改善,而Novartis收购的药物也未能通过三期临床试验。
![]()
By Jason Mast
Nov. 10, 2026
General Assignment Reporter
The biotech PepGen said Tuesday that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a muscle disorder that affects over 100,000 people in the U.S. and Europe.
PepGen is a latecomer to the fight to treat myotonic dystrophy type 1 (DM1), a condition that typically robs patients of muscle control and strength beginning around adolescence. Tuesday’s data come from six patients, who were treated for 12 weeks.
Dyne Therapeutics is close to completing a pivotal trial for a DM1 drug. Novartis just announced that a DM1 drug it acquired in its $12 billion buyout of Avidity Biosciences failed to improve a key measure of muscle control in a Phase 3 trial, casting a pall over the field.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com